ArticleOpen veterinary journal2026
Hepatoprotective effect of dipyridamole against cyclophosphamide-induced hepatotoxicity in rats.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclophosphamide (Cyc) is an anticancer and immunomodulatory drug, but its use is associated with toxicity, including hepatotoxicity, mediated by oxidative stress (OS), lipid peroxidation, and inflammation. Hence, coadministration of antioxidants probably mitigates Cyc-induced hepatotoxicity. Aim: This study assessed the hepatoprotective effect of dipyridamole (Dipyr) against Cyc-induced hepatotoxicity in rats. Methods: Thirty-six rats were divided randomly into six equal groups: normal control, Cyc only, Dipyr only (30 mg/kg), Cyc (200 mg/kg) with low-dose Dipyr (15 mg/kg), Cyc with high-dose Dipyr (30 mg/kg), and corn oil (CO) control. Dipyr treatment lasted 10 consecutive days, and Cyc was injected intraperitoneally on day 9. By the end of the study on day 11, body and liver weights, hematological and oxidative stress parameters, liver function biomarkers, NF-κB expression, and histopathology were assessed. Results: Cyc administration caused hepatomegaly, reduced body weight, leukocytopenia, elevated serum ALT, AST, and ALP levels, increased malondialdehyde and NF-κB levels, and reduced glutathione, catalase, and total antioxidant capacity. Histopathological examination revealed severe hepatocellular toxicity. Dipyr coadministration mitigated Cyc-induced hepatotoxicity dose-dependently, lowering lipid peroxidation, restoring antioxidant levels, suppressing hepatic NF-κB levels, and mitigating histopathological damage. However, Dipyr failed to restore leukocyte counts. Conclusion: These findings confirm Dipyr's protective potential against Cyc-induced hepatotoxicity mainly via antioxidant and anti-inflammatory mechanisms. Dipyr may probably mitigate hepatic injuries when used as an adjuvant in patients undergoing Cyc therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.